Skip to main content

Table 5 Comparison of test and placebo groups in terms of patient satisfaction

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

  Univariable Multivariable
No Yes OR (95% CI) P-value OR (95% CI) P-value
Group
 Active 3 (9.1%) 30 (90.9%) 9.38 (2.36,37.3) 0.001 9.83 (2.40,40.27) 0.001
 Placebo 15 (48.4%) 16 (51.6%) Reference Reference
Sex
 Female 11 (25.6%) 32 (74.4%) 1.46 (0.47,4.53) 0.518 1.77 (0.43,7.33) 0.430
 Male 7 (33.3%) 14 (66.7%) Reference Reference
Marital Status
 Single 7 (29.2%) 17 (70.8%) Reference 0.886 Reference 0.547
 Married 11 (27.5%) 29 (72.5%) 1.09 (0.35,3.33) 1.75 (0.28,10.88)
Duration of Migraine
 ≤2 years 10 (27.8%) 26 (72.2%) 1.04 (0.35,3.12) 0.944 1.10 (0.27,4.46) 0.891
 > 2 years 8 (28.6%) 20 (71.4%) Reference Reference
Age (mean ± SD) 37.39 ± 9.17 36.04 ± 9.48 0.98 (0.93,1.04) 0.602 0.96 (0.86,1.06) 0.399
BMI (mean ± SD) 24.06 ± 2.85 23.94 ± 3.14 0.99 (0.82,1.18) 0.987 1.04 (0.77,1.40) 0.811
  1. BMI Body–mass index, SD Standard deviation, CI Confidence interval